SAVA vs. INVA, IRWD, TYRA, BCYC, ARQT, OCUL, COLL, LQDA, VRNA, and CNTA
Should you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Innoviva (INVA), Ironwood Pharmaceuticals (IRWD), Tyra Biosciences (TYRA), Bicycle Therapeutics (BCYC), Arcutis Biotherapeutics (ARQT), Ocular Therapeutix (OCUL), Collegium Pharmaceutical (COLL), Liquidia (LQDA), Verona Pharma (VRNA), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical preparations" industry.
Innoviva (NASDAQ:INVA) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, community ranking, dividends and media sentiment.
Innoviva has a net margin of 58.21% compared to Innoviva's net margin of 0.00%. Cassava Sciences' return on equity of 28.94% beat Innoviva's return on equity.
Innoviva received 201 more outperform votes than Cassava Sciences when rated by MarketBeat users. However, 66.20% of users gave Cassava Sciences an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
Innoviva has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
99.1% of Innoviva shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 1.4% of Innoviva shares are held by insiders. Comparatively, 12.2% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Cassava Sciences had 5 more articles in the media than Innoviva. MarketBeat recorded 11 mentions for Cassava Sciences and 6 mentions for Innoviva. Cassava Sciences' average media sentiment score of 0.82 beat Innoviva's score of 0.17 indicating that Innoviva is being referred to more favorably in the media.
Innoviva has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -0.38, indicating that its stock price is 138% less volatile than the S&P 500.
Cassava Sciences has a consensus price target of $124.00, suggesting a potential upside of 431.50%. Given Innoviva's higher possible upside, analysts plainly believe Cassava Sciences is more favorable than Innoviva.
Summary
Innoviva beats Cassava Sciences on 11 of the 16 factors compared between the two stocks.
Get Cassava Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cassava Sciences Competitors List
Related Companies and Tools
